Published TCIMAIL newest issue No.200 | Product Document Searching Made Easy by 2D Code! | TCI Life Science News December 2025 | [Product Highlights] Cell Culture-Ready Antibiotic... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
Cathepsin B in the lysosome cleaves the peptide bond between Cit-PAB of dipeptide linkers containing valine (Val)-citrulline (Cit) and p-aminobenzylalcohol (PAB). When PAB and a drug are binded covalently with carbamate bonds, the drug can be released by hydrolysis after cleavage of the peptide bond between Cit-PAB. Antibody-drug conjugates (ADCs) has been developed using this mechanism.
Products
Advantages
- Contain Val-Cit sequence degradable by a lysosome enzyme
- Have superior plasma stability comparable to that of non-cleavable linkers
- Available for manufacturing with several tens gram scale
References
- 1) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.
- 2) A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy
- 3) Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
